WORKSHOP 15

For English see below

Start je eigen farmaceutische bedrijf: een droom of gewoon doen?

Naam: Dr. Cristianne Rijcken

Vooropleiding: Farmacie (Utrecht) gevolgd door promotie (Afdeling Biofarmacie & Farmaceutische technologie, Universiteit Utrecht)

Loopbaan: Na promotie zelf Cristal Therapeutics opgericht in 2011 en tot december 2014 CEO. Inmiddels wordt eerste geneesmiddel in klinische fase I studie bij patiënten geëvalueerd.

CriPec® nanomedicines: building a clinical pipeline of customisable therapeutics

Cristal Therapeutics is a clinical stage company developing nanomedicines for the

treatment of cancer and other diseases. The Company’s product candidates are based on

its proprietary CriPec® polymeric platform, which enables the design of customised

nanomedicines. CriPec®-based products have the potential to provide enhanced efficacy

and reduced side effect profiles over current treatment options available in the clinic. The

lead product, CriPec® docetaxel, is in clinical phase 1b studies for the treatment of solid

tumours, while several other products are in preclinical development.

Beroep: Chief Scientific Officer

Dagelijkse werkzaamheden: Aansturing interne translationele projecten, contact met farmaceutische bedrijven voor (mogelijke) samenwerkingen of uitbesteden van specifieke projecten; verdediging en versteviging patent portfolio, contact met wereldwijde experts en investeerders, aanvragen (inter)nationale subsidie etc.

De workshop: Dagelijkse werkzaamheden: Wat komt er allemaal bij kijken bij het opzetten van een eigen bedrijf? Waarom is het zo enorm uitdagend en geeft ’t zoveel voldoening?

Start your own pharmaceutical company: to do or not to do?

Name: Dr. Christianne Rijcken

Preliminary education: Pharmacy (Utrecht) followed by a PhD (department of Biopharmacy & Pharmaceutical Technology, University of Utrecht).

Career: After finishing her PhD, Christianne started her own company in 2011: Cristal Therapeutics. Until 2014 she was the CEO of this company. Meanwhile, the first drug is being evaluated in a clinical phase 1 study on patients. 

CriPec® nanomedicines: building a clinical pipeline of customisable therapeutics. Cristal Therapeutics is a clinical stage company developing nanomedicines for the treatment of cancer and other diseases. The company’s product candidates are based on its proprietary CriPec® polymeric platform, which enables the design of customised nanomedicines, CriPec® – based products have the potential to provide enhanced efficacy and reduced side effect profiles over current treatment options available in the clinic. The lead product, CriPec® docetaxel, is in clinical phase 1b studies for the treatment of solid tumours, while several other products are in preclinical development.

Profession: Chief Scientific Officer

Daily activities: steering internal translational projects, contact with pharmaceutical companies for (possible) collaborations or outsourcing specific projects; defending and strengthening patent portfolio, contact with worldwide experts and investors, applying for (inter)national subsidy, etc.

This workshop: Daily work: what does it take to set up your own business? What makes it very challenging and why is it so satisfying?